A Phase 3 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy

Trial Profile

A Phase 3 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs CTP 499 (Primary)
  • Indications Diabetic nephropathies
  • Focus Registrational; Therapeutic Use
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2015 According to a Concert Pharmaceuticals media release, the company has reached agreement with the U.S. FDA under a Special Protocol Assessment (SPA) for this trial.
    • 04 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top